Drug ID:Drug188
Drug Name:BL-7040
CID:168325625
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT01506362
Molecular Formula:C194H253N64O106P19S19
Molecular Weight:6375.0 g/mol
Isomeric SMILES:CC1=CN(C(=O)N=C1O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3CO)N4C=CC(=N)N=C4O)OP(=S)(O)OCC5C(CC(O5)N6C=NC7=C6NC(=N)N=C7O)OP(=S)(O)OCC8C(CC(O8)N9C=CC(=N)N=C9O)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=N)N=C1O)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=N
Synonyms:BL-7040
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

No molecular structure data available

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT01506362 Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis PHASE2 COMPLETED BioLineRx, Ltd. Ulcerative Colitis DRUG: BL-7040 Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

No related literature

You can run management commands to establish drug-literature associations